This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Proteasome	<p>Cell culture and mouse studies suggest proteasome inhibitors could help treat basal-like, triple-negative breast cancer. A small interfering RNA screen in two triple-negative breast cancer cell lines identified multiple components of the proteasome that could be inhibited to decrease cell growth. In basal-like, triple-negative breast cancer cell lines, Velcade bortezomib decreased growth, including growth of tumor-initiating cells, compared with vehicle. In a mouse xenograft model of basal-like, triple-negative breast cancer, intratumoral injection of Velcade decreased growth compared with control injection. Next steps include identifying markers to predict triple-negative breast cancer responsiveness to proteasome inhibition.</p> <p>Takeda Pharmaceutical Co. Ltd. and Johnson & Johnson market the competitive proteasome inhibitor Velcade to treat multiple myeloma and mantle cell lymphoma.</p> <p>SciBX 6(35); doi:10.1038/scibx.2013.952 Published online Sept. 12, 2013</p>	Patent application filed; available for licensing	<p>Petrocca, F. <i>et al. Cancer Cell</i>; published online Aug. 12, 2013; doi:10.1016/j.ccr.2013.07.008 Contact: Judy Lieberman, Harvard Medical School, Boston, Mass. e-mail: judy.lieberman@childrens.harvard.edu Contact: Fabio Petrocca, same affiliation as above e-mail: fabio.petrocca@childrens.harvard.edu</p>